Rubia species in traditional Chinese medicine have cytotoxic and antitumor effects, containing specific antitumor agents. Review focuses on 71 chemical substances in Genus Rubia with structures and mechanisms of action.
Study formulated and tested a plant-based extract in PCOS-induced rats. Extract improved ovulation, hormone levels, liver function, and inflammation in ovaries. Potential treatment for PCOS.
Researchers developed a phytosome delivery system for a plant extract with strong antioxidant properties. Formulation improved bioavailability of key compound, leading to increased neuroprotective effects and pain relief potential in nerve damage. Encapsulation may enhance treatment for neuropathic pain.
Scientists synthesized modified analogues of RA-VII peptides from Rubia cordifolia roots, testing them against various cancer cell lines. They found that certain modifications were crucial for potent cytotoxic activity, highlighting potential new treatment strategies.
The study investigated the impact of L. (L.) roots in diabetic neuropathy using a rat model. It examined potential neuroprotective, antidiabetic, and analgesic mechanisms. This research is relevant for understanding diabetic neuropathy treatment options.
YIV-818-A, a botanical drug derived from Rubia cordifolia extracts, effectively inhibits castration-resistant prostate cancer (CRPC) and shows synergy with existing drugs. It has potential as an anti-prostate cancer drug with chemopreventive properties.
Mollugin, a compound from Rubia cordifolia, induces ferroptosis in colorectal cancer (CRC) cells by reducing GSH and increasing ROS, Fe, and MDA levels. Inhibition of ferroptosis reverses the antitumor effects of mollugin. High expression of IGF2BP3 in CRC suggests poor prognosis. Mollugin may be a promising CRC therapy by targeting the IGF2BP3/GPX4 axis.